Serum thrombospondin-2 level changes with liver stiffness improvement in patients with type 2 diabetes.

Jimmy Ho Cheung MakDavid Tak-Wai LuiCarol Ho-Yi FongChloe Yu-Yan CheungYing WongAlan Chun-Hong LeeRuby Lai-Chong HooAimin XuKathryn Choon Beng Tan Karen Siu-Ling LamChi-Ho Lee

Published in: Clinical endocrinology (2023)

Serum TSP2 level decreased with LS after dapagliflozin treatment, and was independent of improvements in BW, glycemic control and hepatic steatosis, further supporting the potential of serum TSP2 level as a novel hepatic fibrosis biomarker in type 2 diabetes.

Keyphrases

glycemic control
type diabetes
blood glucose
insulin resistance
cardiovascular disease
weight loss
human health
combination therapy